Pendopharm, division of Pharmascience Inc., is pleased to announce the recent launch of Octasa® 800 mg (mesalamine) delayed-release tablets, as treatment for moderately active ulcerative colitis (UC) in Canada.
The launch of Octasa® 800 mg represents an important step in Pendopharm’ strategic partnership with Tillotts Pharma AG, part of the Japanese Zeria Group, and a milestone for both organizations.
Canada has one of the highest incidences of Inflammatory Bowel Disease (IBD) in the world, with 7 in 1,000 Canadians affected by the disease. By 2030, the incidence of IBD in Canada is expected to rise to 1% or 1 in 100 (403,000 Canadians).
The introduction of Octasa® 800 mg (mesalamine) delayed-release tablets to the Canadian market is expected to optimize the therapeutic options for UC in Canada.
Jad Isber, Vice President and General Manager at Pendopharm, said:
“We are delighted to continue our strong relationship with Tillotts by bringing Octasa® 800 mg to Canadian patients suffering from moderately active ulcerative colitis. The addition of Octasa® 800 mg to our portfolio will further enhance Pendopharm’s leadership position in gastroenterology, bringing a new treatment option to healthcare professionals and patients.”
Adrian Hill, Global Head of Commercial Operations at Tillotts, added:
“We are very excited to announce that Octasa® 800 mg from Tillotts AG is now available in Canada. The commercial launch of Octasa® 800 mg tablets in Canada will bring a new treatment option in the form of a tablet to clinicians and patients. This has been achieved through the strong strategic partnership between Tillotts and Pendopharm.”
About Pharmascience Inc.
Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience’s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients’ needs.
Pendopharm, division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm has extensive experience and knowledge to successfully manage its growing product portfolio.
For more information about Pendopharm, please visit www.pendopharm.com.
For media inquiries, please contact MediaInquiries@pharmascience.com.
© 2022 Pendopharm, division of Pharmascience Inc. All rights reserved
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 350 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridoides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of partners throughout the world.
The rights to the trademark Octasa® are owned by Tillotts Pharma AG used under license by Pendopharm, division of Pharmascience Inc.
For more information, please visit www.tillotts.com.
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp.
For more information, please contact:
Lead Corporate Communication
Phone: +41 61 935 2626